ArticleTherapeutic advances in medical oncology2025
Clinical and pathological analyses of gastric-type cervical adenocarcinoma and its prognostic relevance.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinicopathological features and survival outcomes of HPV-independent versus HPV-associated cervical adenocarcinoma: a Systematic Review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Artificial intelligence-assisted histopathological diagnosis of endocervical gastric-type adenocarcinoma: a multicenter model development and validation study.The journal of pathology. Clinical research · 2026Article
- Clinicopathological characteristics and outcomes of gastric-type adenocarcinoma of the cervix: a systematic review.AJOG global reports · 2026Review
- Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges.Journal of personalized medicine · 2026Review
- Mutation profile and therapeutic implications in Peutz-Jeghers syndrome-associated gastric-type endocervical adenocarcinoma.Frontiers in oncology · 2026Article
- Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric-type endocervical adenocarcinoma (GAS), the predominant non-human papillomavirus cervical cancer, is highly aggressive with poor prognosis. No drugs are effective against advanced or recurrent GAS. Objective: This study aimed to analyze the clinical and pathological characteristics of GAS, evaluate the expression of targets for targeted drug therapy, and assess the predictive value of Immunoscore for prognosis. Design: The study retrospectively analyzed the clinical and pathological characteristics and follow-up data of 107 cases of GAS and 523 of human papillomavirus-associated cervical adenocarcinoma (HPVA) treated surgically at Zhejiang Cancer Hospital between January 2015 and December 2022. Methods: Immunohistochemistry was used to detect the expressions of Tumor Protein 53 (P53), p16 protein (P16), Human Epidermal Growth Factor Receptor 2, Mucin 6, Programmed Death-Ligand 1 (PD-L1), Claudin 18.2, and immune markers Cluster of Differentiation 3/Cluster of Differentiation 8 in tumors. Ridge regression analysis was employed to obtain an Immunoscore, and receiver-operating characteristic curves were used to calculate the cutoff value to divide the Immunoscores into the low-risk and high-risk groups. The Kaplan-Meier method and Cox proportional hazards regression model were used in the survival and multivariate analyses, respectively. Results: Compared with HPVA, GAS was associated with later staging, larger tumor size, deeper invasion, and higher risks of lymph node metastasis, lymphovascular space invasion, parametrial involvement, ovarian metastasis, and peritoneal metastasis ( Conclusion: GAS is extremely aggressive and prone to recurrence and has a poor prognosis. The Immunoscore is an independent prognostic factor of GAS. Claudin 18.2 is expressed at high rates in GAS and is a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.